Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial
Journal of the National Comprehensive Cancer Network · 2026-07 · 24 (7)
DOI: 10.6004/jnccn.2026.7012 ↗Abstract
Background: The number of cancer survivors is growing rapidly, and >70% are overweight or obese. Given their increased risk for obesity-related conditions (eg, cardiovascular disease, second malignancies), weight-loss interventions are a priority for this population, yet few have access. Patients and Methods: We conducted a 2-arm, single-blinded, randomized controlled trial to test whether a 24-week, fully automated, web-based diet intervention would significantly improve body weight and other health-related outcomes compared with a waitlist control among cancer survivors. The AiM, PLan, and act on LIFestYles (AMPLIFY) diet intervention offered serialized, tailored guidance to achieve a 0.5 kg per week weight loss and improve diet quality. Survivors of 1 of 9 obesity-related cancers with >70% 5-year survival, aged ≥50 years, and with a body mass index of 25 to
EUVIMED